Clinical trial
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma…
NCT04924075 · Merck Sharp & Dohme LLC, Industry · Recruiting
Key facts
| NCT number | NCT04924075 |
|---|---|
| Title | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) |
| Official title | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers |
| Intervention type | Drug |
| Interventions | Belzutifan |
| Enrollment | 322 |
| Start date | Aug 12, 2021 |
| Primary completion | Jun 4, 2029 |
| Completion | Jun 4, 2029 |
| First posted | Jun 11, 2021 |
| Last update posted | Jan 6, 2026 |
| Countries | Australia, Canada, Chile, China, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands and 10 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: